Navigation Links
Molecule identified that increases survival of stomach cancer patients
Date:9/14/2010

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jess Garca-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

Pharmacogenetics studies the genetic bases determining the response of an individual to treatment, as well as possible toxic reactions; pharmacogenomics analyses the molecular and biological mechanisms involved in a disease in order to develop new medicines. "We know that variations in small molecules (microRNAs) give rise to different responses to the same pharmaceutical drug. In this line, a number of approaches are being made in clinical practice, such as the study of mutations of the K-RAS gene in cancer of the colon or of the EGFR in lung cancer, and which enable directing individualised treatment for each patient".

The study presented at this scientific meeting analysed the role of microRNA 451 in stomach cancer, "Patients with a high expression of this molecule show greater survival rates, and so could be a biomarker for treatment response". The CIMA researchers are also taking part in other trials, such as studies with the 192 and 215 microRNAs, which influence the response to pharmaceutical drugs against cancer of the colon, at the preclinical phase.

Psychiatric and cardiovascular diseases

Besides its application in cancer, pharmacogenetics is demonstrating its efficacy in other disciplines such as psychiatry. So today, more individualised treatment can be determined for psychotic disorders and epilepsy for each patient.

Another field that is growing fast is that involving the treatment of cardiovascular diseases. "One of the great risks of these illnesses is controlling the thrombotic processes involved in cerebrovascular accidents. The study of certain genes, such as ALOX5AP, can direct the most appropriate medication for each patient", explained Dr. Garca-Foncillas.

In the opinion of the CIMA researcher, "the convergence of genetic and pharmacological studies has created a way for optimising both the treatment for each patient as well as health resources, given that we will be able to use pharmaceutical drugs in suitable doses, with fewer side effects and with patients that show better therapeutic response".


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
0034-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Scientists identify molecules involved in touch and other mechanically activated systems
2. Juelich researchers take a look inside molecules
3. Molecules delivering drugs as they walk
4. One molecule, many more insulin-producing cells to treat diabetes, says Pitt team
5. Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells
6. Correcting a trick of the light brings molecules into view
7. Molecules typically found in blue jean and ink dyes may lead to more efficient solar cells
8. Stretching molecules yields new understanding of electricity
9. Single-molecule manipulation for the masses
10. Scripps research scientists determine structure of immune molecule that counteracts HIV strains
11. New bacterial signaling molecule could lead to improved vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... Bank, today announced first round funding to three startups through the UConn Innovation ... support to new business startups affiliated with UConn. , The UConn Innovation Fund ...
(Date:4/21/2017)... Muncie, IN (PRWEB) , ... April 21, 2017 , ... ... year to 11 high school graduates from across the nation. The scholarships are created ... of AMA member dues. , Scholarship criteria are set by the AMA Scholarship Committee, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
Breaking Biology Technology: